[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:atopic-dermatitis":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":311,"states":312},"Atopic Dermatitis",89,66,[8,16,23,29,35,41,47,53,60,66,72,78,84,90,96,102,108,114,120,126,132,138,144,150,156,162,168,174,180,186,192,198,204,210,216,222,228,233,239,245,251,257,263,269,275,281,287,293,299,305],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07216027","A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema",[12],"Phase 2","RECRUITING","2026-08-26T02:17:58.890423Z","2026-07-30T01:46:14.417189Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06808477","A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)",[20],"Phase 1","2026-08-26T02:15:37.042762Z","2026-07-19T19:36:05.057971Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06504160","Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)",[20],"2026-08-26T02:16:32.589113Z","2026-07-05T05:32:16.756701Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07003425","A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis",[12],"2026-08-26T02:14:59.425132Z","2026-07-05T05:32:16.724026Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT07453602","Ph 1a\u002F1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234",[20],"2026-08-26T02:17:53.433613Z","2026-07-05T05:32:16.683143Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT07355075","A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)",[12],"2026-08-26T02:19:06.150683Z","2026-07-05T05:32:16.676552Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT07599813","A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis",[12],"2026-08-26T02:17:26.640202Z","2026-05-29T15:36:40.218903Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":58,"content_modified":59},"NCT07560618","Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.",[57],"Phase 4","2026-08-26T02:16:20.336282Z","2026-05-13T02:55:06.726393Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT07558668","A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis",[20],"2026-08-26T02:17:38.215063Z","2026-05-13T02:55:06.724251Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":27,"content_modified":71},"NCT06461897","A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis",[70],"Phase 3","2026-05-05T02:43:29.187688Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06116526","Dupilumab De-escalation in Pediatric Atopic Dermatitis",[57],"2026-08-26T02:17:25.718160Z","2026-05-05T02:43:29.184359Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06564389","FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients",[20],"2026-08-26T02:18:19.586423Z","2026-05-05T02:43:28.871870Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06947993","Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis",[12],"2026-08-26T02:18:31.944757Z","2026-05-05T02:43:28.728431Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06397911","Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis",[12],"2026-08-26T02:16:46.147215Z","2026-05-05T02:43:28.714571Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT05285839","Dupixent and Narrowband UVB for Atopic Dermatitis",[57],"2026-08-26T02:19:21.761002Z","2026-05-05T02:43:28.705106Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT07265479","A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to \u003C 24 Months With Atopic Dermatitis",[70],"2026-08-03T02:11:04.414058Z","2026-05-05T02:43:28.347768Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT06096857","Cardamom and Topical Roseomonas in Atopic Dermatitis",[12],"2026-08-26T02:18:58.958025Z","2026-05-05T02:43:28.301594Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT06389136","A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab",[70],"2026-08-26T02:17:05.172421Z","2026-05-05T02:43:28.297228Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT05995964","A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis",[12],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:28.291367Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT06807281","A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema",[70],"2026-08-26T02:17:41.695983Z","2026-05-05T02:43:28.187882Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT07298395","Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis",[12],"2026-08-26T02:19:17.380174Z","2026-05-05T02:43:27.923689Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT07277660","A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis",[12],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:27.798064Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT07223697","A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis",[12],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:27.797527Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT06241118","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor",[70],"2026-08-26T02:18:36.226508Z","2026-05-05T02:43:27.308600Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT06311682","A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis",[70],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:27.102359Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT06055361","A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis",[20],"2026-08-26T02:15:25.633039Z","2026-05-05T02:43:27.101777Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT07441395","Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD",[12],"2026-08-26T02:16:17.877565Z","2026-05-05T02:43:26.925565Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT05042258","Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate\u002FSevere Atopic Dermatitis",[57],"2026-08-26T02:16:34.792807Z","2026-05-05T02:35:31.932192Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT01631617","Effects of Treatments on Atopic Dermatitis",[12],"2026-08-26T02:18:23.582895Z","2026-05-05T02:35:31.878983Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT06982352","Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis",[20],"2026-08-26T02:16:13.426928Z","2026-05-05T02:35:31.599086Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT07037901","A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis",[12],"2026-08-26T02:15:13.282904Z","2026-04-29T02:57:57.157754Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT06807268","A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema",[70],"2026-08-26T02:18:34.622081Z","2026-04-29T02:57:57.063175Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT07262983","Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and\u002For Atopic Dermatitis",[20],"2026-08-26T02:18:46.948970Z","2026-05-05T02:43:29.363269Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT07242638","Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome",[12],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:27.399225Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT03835767","Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis",[12],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.662537Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":226,"content_modified":227},"NCT07690371","A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis",[70],"2026-08-26T02:15:42.447052Z","2026-07-19T19:36:05.152367Z",{"nct_id":229,"title":224,"phases":230,"status":13,"updated_at":231,"content_modified":232},"NCT07711418",[70],"2026-08-26T02:15:41.377360Z","2026-07-19T19:36:05.093507Z",{"nct_id":234,"title":235,"phases":236,"status":13,"updated_at":237,"content_modified":238},"NCT06238765","CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry",[],"2026-08-26T02:17:42.501124Z","2026-07-05T05:32:16.745671Z",{"nct_id":240,"title":241,"phases":242,"status":13,"updated_at":243,"content_modified":244},"NCT07645820","Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares",[],"2026-08-26T02:18:48.678868Z","2026-06-14T18:39:22.264627Z",{"nct_id":246,"title":247,"phases":248,"status":13,"updated_at":249,"content_modified":250},"NCT07643766","A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis",[12],"2026-08-26T02:15:40.343619Z","2026-06-14T18:39:22.262558Z",{"nct_id":252,"title":253,"phases":254,"status":13,"updated_at":255,"content_modified":256},"NCT05721937","A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring",[],"2026-08-26T02:15:52.238965Z","2026-05-29T15:36:40.174629Z",{"nct_id":258,"title":259,"phases":260,"status":13,"updated_at":261,"content_modified":262},"NCT07290803","This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment",[],"2026-08-26T02:17:00.709807Z","2026-05-13T02:55:06.685688Z",{"nct_id":264,"title":265,"phases":266,"status":13,"updated_at":267,"content_modified":268},"NCT06998446","Sodium in the Skin and Atopic Dermatitis",[],"2026-08-26T02:19:27.519777Z","2026-05-13T02:55:06.604857Z",{"nct_id":270,"title":271,"phases":272,"status":13,"updated_at":273,"content_modified":274},"NCT06988605","Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults",[],"2026-08-26T02:17:44.240289Z","2026-05-13T02:55:06.603789Z",{"nct_id":276,"title":277,"phases":278,"status":13,"updated_at":279,"content_modified":280},"NCT06899204","Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.",[],"2026-08-26T02:16:04.914942Z","2026-05-13T02:55:06.589265Z",{"nct_id":282,"title":283,"phases":284,"status":13,"updated_at":285,"content_modified":286},"NCT06627335","An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis",[],"2026-08-26T02:15:00.557154Z","2026-05-13T02:55:06.556715Z",{"nct_id":288,"title":289,"phases":290,"status":13,"updated_at":291,"content_modified":292},"NCT06259669","Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population",[],"2026-08-26T02:19:12.219640Z","2026-05-13T02:55:06.429475Z",{"nct_id":294,"title":295,"phases":296,"status":13,"updated_at":297,"content_modified":298},"NCT06136767","Registry for Systemic Eczema Treatments",[],"2026-08-26T02:18:27.904411Z","2026-05-13T02:55:06.417552Z",{"nct_id":300,"title":301,"phases":302,"status":13,"updated_at":303,"content_modified":304},"NCT05938478","Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT",[],"2026-08-26T02:17:49.709549Z","2026-05-13T02:55:06.395695Z",{"nct_id":306,"title":307,"phases":308,"status":13,"updated_at":309,"content_modified":310},"NCT04455906","Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism",[],"2026-08-26T02:16:03.788292Z","2026-05-13T02:55:06.251962Z",[],[313,317,321,325,329,333,337,341,345,349,352,356,359,363,366,370,373,377,380,383,387,391,394,397],{"state":314,"count":315,"slug":316},"California",47,"california",{"state":318,"count":319,"slug":320},"Florida",32,"florida",{"state":322,"count":323,"slug":324},"Texas",31,"texas",{"state":326,"count":327,"slug":328},"New York",28,"new-york",{"state":330,"count":331,"slug":332},"Michigan",26,"michigan",{"state":334,"count":335,"slug":336},"Illinois",23,"illinois",{"state":338,"count":339,"slug":340},"Pennsylvania",22,"pennsylvania",{"state":342,"count":343,"slug":344},"Indiana",20,"indiana",{"state":346,"count":347,"slug":348},"Maryland",19,"maryland",{"state":350,"count":347,"slug":351},"Ohio","ohio",{"state":353,"count":354,"slug":355},"Alabama",17,"alabama",{"state":357,"count":354,"slug":358},"Georgia","georgia",{"state":360,"count":361,"slug":362},"Arkansas",15,"arkansas",{"state":364,"count":361,"slug":365},"South Carolina","south-carolina",{"state":367,"count":368,"slug":369},"North Carolina",14,"north-carolina",{"state":371,"count":368,"slug":372},"Oregon","oregon",{"state":374,"count":375,"slug":376},"Arizona",13,"arizona",{"state":378,"count":375,"slug":379},"Kentucky","kentucky",{"state":381,"count":375,"slug":382},"Massachusetts","massachusetts",{"state":384,"count":385,"slug":386},"Missouri",11,"missouri",{"state":388,"count":389,"slug":390},"Colorado",9,"colorado",{"state":392,"count":389,"slug":393},"Nevada","nevada",{"state":395,"count":389,"slug":396},"New Jersey","new-jersey",{"state":398,"count":389,"slug":399},"Virginia","virginia"]